202 related articles for article (PubMed ID: 26121345)
21. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26422095
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study.
Zhao J; Li J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P
Clin Ther; 2006 Nov; 28(11):1868-76. PubMed ID: 17213007
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD.
Hussain S; Kierkus J; Hu P; Hoffman D; Lekich R; Sloan S; Treem W
J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):226-36. PubMed ID: 24121146
[TBL] [Abstract][Full Text] [Related]
24. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study.
Zeng J; Zuo XL; Li YQ; Wei W; Lv GP
Eur J Clin Pharmacol; 2007 Jun; 63(6):529-36. PubMed ID: 17468863
[TBL] [Abstract][Full Text] [Related]
25. The effect of antireflux treatment on the frequency of awakenings from sleep in patients with Gastroesophageal reflux disease.
Jha LK; Maradey-Romero C; Gadam R; Hershcovici T; Fass OZ; Quan SF; Guillen J; Fass R
Neurogastroenterol Motil; 2015 Feb; 27(2):237-45. PubMed ID: 25484104
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of esomeprazole for treatment of poorly controlled asthma.
; Mastronarde JG; Anthonisen NR; Castro M; Holbrook JT; Leone FT; Teague WG; Wise RA
N Engl J Med; 2009 Apr; 360(15):1487-99. PubMed ID: 19357404
[TBL] [Abstract][Full Text] [Related]
27. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study.
Kiljander TO; Junghard O; Beckman O; Lind T
Am J Respir Crit Care Med; 2010 May; 181(10):1042-8. PubMed ID: 20110554
[TBL] [Abstract][Full Text] [Related]
28. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
29. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life.
Takeshima F; Hashiguchi K; Onitsuka Y; Tanigawa K; Minami H; Matsushima K; Akazawa Y; Shiozawa K; Yamaguchi N; Taura N; Ohnita K; Ichikawa T; Isomoto H; Nakao K
Med Sci Monit; 2015 Dec; 21():4111-21. PubMed ID: 26719012
[TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
[No Abstract] [Full Text] [Related]
31. Effect of Postprandial Administration of Esomeprazole on Reflux Symptoms in Gastroesophageal Reflux Disease: A Randomized, Controlled Trial.
Boltin D; Zvidi I; Raskin M; Kayless H; Schmilovitz-Weiss H; Gingold-Belfer R; Niv Y; Dickman R
Dig Dis; 2018; 36(4):257-263. PubMed ID: 29791895
[TBL] [Abstract][Full Text] [Related]
32. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
Sakurai K; Suda H; Fujie S; Takeichi T; Okuda A; Murao T; Hasuda K; Hirano M; Ito K; Tsuruta K; Hattori M
Dig Dis Sci; 2019 Mar; 64(3):815-822. PubMed ID: 30415407
[TBL] [Abstract][Full Text] [Related]
33. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
Orenstein SR; Gremse DA; Pantaleon CD; Kling DF; Rotenberg KS
Clin Ther; 2005 Apr; 27(4):472-83. PubMed ID: 15922820
[TBL] [Abstract][Full Text] [Related]
34. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease.
Tolia V; Bishop PR; Tsou VM; Gremse D; Soffer EF; Comer GM;
J Pediatr Gastroenterol Nutr; 2006 Apr; 42(4):384-91. PubMed ID: 16641576
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
[TBL] [Abstract][Full Text] [Related]
36. Cost analysis of long-term treatment of patients with symptomatic gastroesophageal reflux disease (GERD) with esomeprazole on-demand treatment or esomeprazole continuous treatment: an open, randomized, multicenter study in Switzerland.
Szucs T; Thalmann C; Michetti P; Beglinger C
Value Health; 2009; 12(2):273-81. PubMed ID: 18783388
[TBL] [Abstract][Full Text] [Related]
37. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.
Johnson DA; Orr WC; Crawley JA; Traxler B; McCullough J; Brown KA; Roth T
Am J Gastroenterol; 2005 Sep; 100(9):1914-22. PubMed ID: 16128933
[TBL] [Abstract][Full Text] [Related]
38. Esomeprazole reduces gastroesophageal reflux after beer consumption in healthy volunteers.
Franke A; Hepp C; Harder H; Beglinger C; Singer MV
Scand J Gastroenterol; 2008; 43(12):1425-31. PubMed ID: 18924018
[TBL] [Abstract][Full Text] [Related]
39. Predictors of heartburn resolution and erosive esophagitis in patients with GERD.
Orlando RC; Monyak JT; Silberg DG
Curr Med Res Opin; 2009 Sep; 25(9):2091-102. PubMed ID: 19601705
[TBL] [Abstract][Full Text] [Related]
40. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
Tack J; Vladimirov B; Horny I; Chong CF; Eisner J; Czerniak R; Takanami Y
Neurogastroenterol Motil; 2023 Jan; 35(1):e14468. PubMed ID: 36178335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]